Free tool
Drug Trial Radar: Dermatology
Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
93
Completed, industry sponsors, Dermatology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
93 trials
Showing 1 to 25, recently updated first.
Sun Pharmaceutical Industries LimitedIndustry
NCT06415279 · 40 participants · Start Feb 14, 2024 · Primary completion Feb 12, 2025
Drug: Winlevi (clascoterone) 1% cream · For: Acne Vulgaris
Sites: High Point, North Carolina
Sun Pharmaceutical Industries LimitedIndustry
NCT06415305 · 10 participants · Start Sep 1, 2023 · Primary completion Apr 17, 2024
Drug: Winlevi (clascoterone) 1% cream · For: Acne Vulgaris
Sites: Louisville, Kentucky
Sun Pharmaceutical Industries LimitedIndustry
NCT06336603 · 20 participants · Start Nov 15, 2023 · Primary completion Oct 29, 2024
Drug: Winlevi (clascoterone) 1% & Adapalene 0.3% gel · For: Acne Vulgaris
Sites: Louisville, Kentucky
Sun Pharmaceutical Industries LimitedIndustry
NCT06336629 · 10 participants · Start Nov 15, 2023 · Primary completion Jul 10, 2024
Drug: Winlevi (clascoterone) 1% & Duac gel · For: Acne Vulgaris
Sites: Louisville, Kentucky
- Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%Pivotal-lookingCompleted
LEO PharmaIndustry
NCT01926496 · 485 participants · Start Sep 11, 2013 · Primary completion Jul 11, 2019
Drug: Ingenol Mebutate Gel, 0.015%; Imiquimod Cream, 5% · For: Actinic Keratosis (AK)
Sites: Angers, France; Besançon, France; Bobigny, France · 46 sites in all
Sun Pharmaceutical Industries LimitedIndustry
NCT06415292 · 50 participants · Start Nov 27, 2023 · Primary completion Dec 16, 2023
Drug: Winlevi (clascoterone) 1% cream · For: Acne Vulgaris
Sites: High Point, North Carolina
- Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or ScalpPivotal-lookingCompleted
LEO PharmaIndustry
NCT02406014 · 502 participants · Start Apr 2015 · Primary completion Jun 2016
Drug: Ingenol Mebutate Gel, 0.015%; Diclofenac sodium gel 3% · For: Actinic Keratosis (AK)
Sites: Schweinfurt, Germany
Almirall, S.A.Industry
NCT05741294 · 334 participants · Start Jan 20, 2023 · Primary completion Jan 19, 2024
Drug: Tirbanibulin 2.5 mg ointment · For: Actinic Keratosis
Sites: Cagliari, Italy; Catania, Italy; Naples, Italy · 37 sites in all
- Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar FormationPivotal-lookingCompleted
Galderma R&DIndustry
NCT04856904 · 121 participants · Start May 28, 2021 · Primary completion Feb 8, 2023
Drug: Trifarotene Cream; Trifarotene Vehicle Cream · For: Acne Vulgaris
Sites: Scottsdale, Arizona; Fort Smith, Arkansas; Santa Monica, California · 18 sites in all
- A Clinical Trial to Evaluate the Efficacy of Two Acne TreatmentsPivotal-lookingCompleted
Galderma R&DIndustry
NCT02755545 · 127 participants · Start May 1, 2016 · Primary completion Apr 4, 2017
Drug: Product A; Product B · For: Acne
Sites: Richardson, Texas
- AkLief Evaluation in Acne-induced Post-Inflammatory HyperpigmentationPivotal-lookingCompleted
Galderma R&DIndustry
NCT05089708 · 123 participants · Start Dec 22, 2021 · Primary completion Dec 15, 2022
Drug: Trifarotene Cream; Trifarotene Vehicle Cream · For: Acne Vulgaris
Sites: Fountain Valley, California; Fremont, California; San Diego, California · 25 sites in all
LEO PharmaIndustry
NCT00417937 · 98 participants · Start Jan 2007 · Primary completion Jun 2007
Drug: azelaic acid 15% gel; azelaic acid 15% gel · For: Papulopustular Rosacea
Sites: Berlin, Germany
Galderma R&DIndustry
NCT02321098 · 50 participants · Start Feb 2014 · Primary completion Jan 2016
Drug: Loceryl NL + Cosmetic varnish; Loceryl NL 12 weeks and 1 more · For: Foot Dermatoses
Sites: Reykjavik, Iceland
Galderma R&DIndustry
NCT02899000 · 186 participants · Start Jul 29, 2016 · Primary completion Mar 28, 2017
Drug: Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel; Oral doxycycline hyclate · For: Acne Vulgaris
Sites: Fort Worth, Texas
- Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical TrialPivotal-lookingCompleted
Pierre Fabre MedicamentIndustry
NCT04875026 · 146 participants · Start Feb 16, 2021 · Primary completion Jan 31, 2022
Drug: 5-fluorouracil 4% (Tolak) · For: Actinic Keratoses
Sites: Arras, France; Nantes, France; Pau, France · 27 sites in all
Galderma R&DIndustry
NCT02735421 · 67 participants · Start May 13, 2016 · Primary completion Jun 5, 2017
Drug: ABPO Forte Gel; Vehicle gel · For: Acne Vulgaris; Atrophic Acne Scars
Sites: Markham, Canada; Oakville, Canada; Toronto, Canada · 7 sites in all
Galderma R&DIndustry
NCT00892281 · 1,421 participants · Start Apr 2009 · Primary completion Oct 2009
Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy; doxycycline (Oracea®) 40 mg modified release as add-on therapy · For: Rosacea
Sites: Lexington, Kentucky
Galderma R&DIndustry
NCT01909713 · 35 participants · Start May 2013 · Primary completion Jun 2013
Drug: Facial Cleanser and Moisturizer SPF 30 · For: Acne Prone Skin
Sites: Irving, Texas
Galderma R&DIndustry
NCT00671749 · 100 participants · Start Dec 2007 · Primary completion Aug 2008
Drug: adapalene gel, 0.3%; clindamycin/benzoyl peroxide gel · For: Acne Vulgaris
Sites: Sacramento, California; Louisville, Kentucky; Warren, Ohio · 4 sites in all
Galderma R&DIndustry
NCT01951417 · 81 participants · Start Oct 2013 · Primary completion Mar 2014
Drug: Adapalene/BPO Gel · For: Acne
Sites: Boynton Beach, Florida; Nashville, Tennessee; Carrollton, Texas · 5 sites in all
Galderma R&DIndustry
NCT02249104 · 28 participants · Start Aug 2014 · Primary completion Feb 2015
Drug: Adapalene/benzoyl peroxide gel, 0.1%/2.5% · For: Acne Vulgaris
Sites: Pflugerville, Texas
Galderma R&DIndustry
NCT01872715 · 24 participants · Start Mar 2013 · Primary completion Jun 2013
Drug: Oracea · For: Papulopustular Rosacea
Sites: Carrollton, Texas
Galderma R&DIndustry
NCT01209949 · 30 participants · Start Oct 2010 · Primary completion Jan 2011
Drug: Adapalene 0.1% and Benzoyl Peroxide 2.5% gel · For: Acne Vulgaris
Sites: Carrollton, Texas
- Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin GelCompleted
Galderma R&DIndustry
NCT01522456 · 73 participants · Start Apr 2012 · Primary completion May 2012
Drug: Epiduo Gel; Retin-A Micro Microsphere 0.1% · For: Acne Vulgaris
Sites: Dallas, Texas
- Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs PlaceboPivotal-lookingCompleted
Galderma R&DIndustry
NCT01426269 · 235 participants · Start Sep 2011 · Primary completion Jun 2013
Drug: Doxycycline; Metronidazole and 1 more · For: Rosacea
Sites: Santa Monica, California; Coral Gables, Florida; Corbin, Kentucky · 11 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.